What is next for IPIX after successful B-CV19 resu
Post# of 72447
(Total Views: 884)
Posted On: 06/09/2021 2:53:21 PM
What is next for IPIX after successful B-CV19 results? The short answer is that none of us know.
The only thing I am certain of is that Leo will have numerous options and will take the path that he feels will maximize shareholder value. There is an old joke that opinions are like a part of the human body that I cannot say on a message board. The punchline is that everybody has one. With that said my guesses are in chronologically reverse order.
I believe ultimately that Leo will get an offer that he can’t refuse for a complete buyout of IPIX. I personally believe this will not happen for 3-5 years. I believe with each milestone achieved that IPIX and its portfolio become more and more valuable and any buyout offers will drastically increase. In this timeframe Brilacidin will be a multiple billion dollar per year drug producing massive royalty payments. Brilacidin will be generating revenue from multiple instances (Broad Spectrum antiviral/antibacterial/anti inflammation drug, B-IBD UC, B-IBD UPS, B-OM and others. Kevetrin will be advanced through multiple phase 2 and phase 3 trials and possibly be fully approved at this point to treat multiple cancer types as a first line treatment and possibly as an adjuvant with other treatments. IPIX will be primarily a high volume royalty company with low overhead producing massive earnings. IPIX SP will reflect that of a highly profitable, high growth company. A buyout would be at a premium to a SP that reflects the above success.
Intermediately there may be a BP that wants exclusive rights to all Brilacidin instances. No one knows the value of this better than Leo does and I personally think this is a longshot short term but could very well be sold off at some point with a huge upfront payment along with built in milestone payments and ongoing juicy annual royalty payments . This would make IPIX a money machine that collects royalty payments and in turn distributes a portion directly to shareholders with significant resources to advance Kevetrin to be the second franchise drug gold mine. I believe if this scenario plays out it will be after multiple instances of Brilacidin are fully approved. Both Leo and prospective BP partners know that the value of a Brilacidin franchise will continue to increase with time and multiple instances to market. Leo may rinse and repeat this Brilacidin model and position Kevetrin as a 2nd franchise exclusive deal prior to selling the company.
The reason I am listing the short term scenarios last is that there are many possibilities and opportunities that Leo will be approached with. I have stated numerous times that the 2 key milestones are successful trial results which in turn will produce multiple funding options. One possibility is that one or more government agencies grant IPIX funding and Emergency Use Authorization (EUA). In this scenario IPIX would not need a BP partner other than possibly as distribution vehicle in some locations. With IPIX’s extremely low overhead a small percentage of this EUA revenue would pay for manufacturing costs with the majority going to IPIX’s bottom line as earnings. The partnering government/s would assist in an accelerated Phase 3 which would lead to full market approval. A second option is that a BP could offer a lucrative royalty partnership to take on all responsibility for B-CV19 and Broad Spectrum opportunities which would include manufacturing and distribution. There very well could be a mix of the above 2 options separated by different countries and regions. A third option could be a private entity like a SPAC that would bring in significant funding for IPIX to go it alone. Brilacidin is a fully developed drug so funding would be spent on developing multiple delivery mechanisms (pill, IV, inhaler) and cover the costs to manufacture and distribute. Unlike the first 2 options IPIX would have to increase staffing but would be securing the majority of the entire revenue pie vs getting royalty payments.
All of the above options are good options for IPIX shareholders. I believe good trial results will lead to one or more of the above funding options which will in turn lead to many milestone achievements. As IPIX shareholders we will start to be rewarded for our patience this fall as our investment continues to be de-risked and IPIX SP begins to reflect the value of IPIX’s life saving drugs. As risk is decreased, milestones are met and revenue increases we will see an exponential increase in IPIX SP.
The only thing I am certain of is that Leo will have numerous options and will take the path that he feels will maximize shareholder value. There is an old joke that opinions are like a part of the human body that I cannot say on a message board. The punchline is that everybody has one. With that said my guesses are in chronologically reverse order.
I believe ultimately that Leo will get an offer that he can’t refuse for a complete buyout of IPIX. I personally believe this will not happen for 3-5 years. I believe with each milestone achieved that IPIX and its portfolio become more and more valuable and any buyout offers will drastically increase. In this timeframe Brilacidin will be a multiple billion dollar per year drug producing massive royalty payments. Brilacidin will be generating revenue from multiple instances (Broad Spectrum antiviral/antibacterial/anti inflammation drug, B-IBD UC, B-IBD UPS, B-OM and others. Kevetrin will be advanced through multiple phase 2 and phase 3 trials and possibly be fully approved at this point to treat multiple cancer types as a first line treatment and possibly as an adjuvant with other treatments. IPIX will be primarily a high volume royalty company with low overhead producing massive earnings. IPIX SP will reflect that of a highly profitable, high growth company. A buyout would be at a premium to a SP that reflects the above success.
Intermediately there may be a BP that wants exclusive rights to all Brilacidin instances. No one knows the value of this better than Leo does and I personally think this is a longshot short term but could very well be sold off at some point with a huge upfront payment along with built in milestone payments and ongoing juicy annual royalty payments . This would make IPIX a money machine that collects royalty payments and in turn distributes a portion directly to shareholders with significant resources to advance Kevetrin to be the second franchise drug gold mine. I believe if this scenario plays out it will be after multiple instances of Brilacidin are fully approved. Both Leo and prospective BP partners know that the value of a Brilacidin franchise will continue to increase with time and multiple instances to market. Leo may rinse and repeat this Brilacidin model and position Kevetrin as a 2nd franchise exclusive deal prior to selling the company.
The reason I am listing the short term scenarios last is that there are many possibilities and opportunities that Leo will be approached with. I have stated numerous times that the 2 key milestones are successful trial results which in turn will produce multiple funding options. One possibility is that one or more government agencies grant IPIX funding and Emergency Use Authorization (EUA). In this scenario IPIX would not need a BP partner other than possibly as distribution vehicle in some locations. With IPIX’s extremely low overhead a small percentage of this EUA revenue would pay for manufacturing costs with the majority going to IPIX’s bottom line as earnings. The partnering government/s would assist in an accelerated Phase 3 which would lead to full market approval. A second option is that a BP could offer a lucrative royalty partnership to take on all responsibility for B-CV19 and Broad Spectrum opportunities which would include manufacturing and distribution. There very well could be a mix of the above 2 options separated by different countries and regions. A third option could be a private entity like a SPAC that would bring in significant funding for IPIX to go it alone. Brilacidin is a fully developed drug so funding would be spent on developing multiple delivery mechanisms (pill, IV, inhaler) and cover the costs to manufacture and distribute. Unlike the first 2 options IPIX would have to increase staffing but would be securing the majority of the entire revenue pie vs getting royalty payments.
All of the above options are good options for IPIX shareholders. I believe good trial results will lead to one or more of the above funding options which will in turn lead to many milestone achievements. As IPIX shareholders we will start to be rewarded for our patience this fall as our investment continues to be de-risked and IPIX SP begins to reflect the value of IPIX’s life saving drugs. As risk is decreased, milestones are met and revenue increases we will see an exponential increase in IPIX SP.
(17)
(0)